Clinical Trials Browser

Phase 2/3 × Pancreatic Adenocarcinoma × folfirinox × Clear all

NCT05181605 2022-08-09

Survival Analysis After Neoadjuvant Therapy in Patients With Resectable Pancreatic Cancer and Risk Factors

Phase 2/3 Unknown

Gastrointestinal

Pancreatic Adenocarcinoma